The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

But a pair of treatments that launched in 2019 are already offsetting Humira's losses. Combined sales of Skyrizi, a psoriasis ...

AbbVie (NYSE: ABBV) could be the poster child for how to effectively navigate a patent cliff. When Abbott Labs spun off ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations. Read more about ABBV stock here.

Looking at the universe of stocks we cover at Dividend Channel, on 1/15/25, Abbott Laboratories (Symbol: ABT), AbbVie Inc (Symbol: ABBV), and Phillips Edison & Co Inc (Symbol: PECO) will all trade ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

The dividend is significant to AbbVie: The company is a Dividend King, with a decades-long history of yearly increases from when it was still part of Abbott Labs. Investors can probably expect mid ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...